Meredith Hatcher, PA
Physician Assistant · Georgetown, TXNPI 1134631450
Payments from drug & device makers
Across 835 payments — averaging $127.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$73K
- Merz Pharmaceuticals, LLC$12K
- Amneal Pharmaceuticals LLC$3K
- Acorda Therapeutics, Inc$3K
- Abbott$3K
- MDD US Operations, LLC$2K
- plus $10K from 23 others
Across 2 payments — averaging $245.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$490
What the payments were for
- Consulting fees$13,30424%
- Speaking & faculty fees$23,23242%
- Travel & lodging$2,7785%
- Food & beverage$15,37628%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 145 | $72,897 |
| Merz Pharmaceuticals, LLC | 142 | $11,663 |
| Amneal Pharmaceuticals LLC | 33 | $3,463 |
| Acorda Therapeutics, Inc | 19 | $3,429 |
| Abbott | 55 | $2,791 |
| MDD US Operations, LLC | 56 | $2,490 |
| Medtronic | 65 | $2,258 |
| Acadia Pharmaceuticals Inc | 63 | $2,228 |
| Neurocrine Biosciences, Inc. | 85 | $1,109 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,100 |
| Biogen | 2 | $693 |
| Kyowa Kirin, Inc. | 29 | $631 |
| Sunovion Pharmaceuticals Inc. | 25 | $339 |
| Ipsen Biopharmaceuticals, Inc | 7 | $163 |
| GE HealthCare | 8 | $150 |
| Arbor Pharmaceuticals, Inc. | 9 | $136 |
| Cala Health, Inc. | 3 | $122 |
| Insightec,inc | 6 | $122 |
| Azurity Pharmaceuticals, Inc. | 6 | $120 |
| Avion Pharmaceuticals | 5 | $109 |
| Adamas Pharmaceuticals, Inc. | 4 | $81 |
| Avanir Pharmaceuticals, Inc. | 4 | $79 |
| Revance Therapeutics, Inc. | 2 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Boston Scientific | 3 | $44 |
| UCB, Inc. | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Corium, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,428 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 168 | $1,338,254 |
| RytaryCarbidopa/Levodopa | 442 | $895,404 |
| IngrezzaValbenazine Tosylate | 60 | $521,264 |
| GocovriAmantadine Hcl | 135 | $349,785 |
| NourianzIstradefylline | 94 | $338,610 |
| AustedoDeutetrabenazine | 44 | $265,767 |
| InbrijaLevodopa | 43 | $197,885 |
| Droxidopa | 34 | $134,001 |
| NuedextaDextromethorphan Hbr/Quinidine | 51 | $83,496 |
| NeuproRotigotine | 33 | $55,620 |
| HorizantGabapentin Enacarbil | 33 | $43,197 |
| OngentysOpicapone | 31 | $39,758 |
| MyrbetriqMirabegron | 44 | $35,971 |
| XadagoSafinamide Mesylate | 16 | $30,275 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 205 | $17,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $2,228 | $1,338,254168 claims |
| Amneal Pharmaceuticals LLCRytary | $3,463 | $895,404442 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,109 | $561,02291 claims |
| MDD US Operations, LLCGocovri | $2,490 | $349,785135 claims |
| Kyowa Kirin, Inc.Nourianz | $631 | $338,61094 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,100 | $265,76744 claims |
| Acorda Therapeutics, IncInbrija | $3,429 | $197,88543 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $79 | $83,49651 claims |
| UCB, Inc.Neupro | $31 | $55,62033 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $136 | $43,19733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Georgetown
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.